ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after three monthly doses.

RHHBY says the ZUPREME-1 study meets its goal as petrelintide delivers up to 10.7% weight loss with placebo-like tolerability ...

Skye Bioscience Inc (SKYE) reports promising weight loss results and strategic R&D collaborations, despite challenges in dosing and delivery.

ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after ...

Using proprietary copolymer technology, TEV-’749 allows for a controlled steady release of olanzapine, a second generation antipsychotic.

Roche Group AG’s RHHBY obesity drug push faces stiff competition after Genentech, a unit of Roche, reported Phase 2 results showing up to 10.7% weight loss—below expectations and lagging leading ...

Compounded NAD+ Telehealth Access, FDA Classification, Pharmacy Sourcing Standards, Prescription Requirements, and Consumer ...

The company is pursuing a Phase 3 trial in its most exciting pipeline drug, and investors are awaiting potentially exciting ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase II ZUPREME-1 trial evaluating investigational petrelintide versus placebo ...

This once-weekly C-type natriuretic peptide analog functions by antagonizing overactive FGFR3 signaling to improve growth in pediatric patients.

As NAD+ injections and IV drips trend from TikTok to the Kardashians, the science of longevity remains a work in progress. Explore the benefits, side effects, and the debate between oral precursors ...

Efgartigimod led to statistically significant improvement in key symptoms of ocular myasthenia gravis compared with placebo in a phase 3 trial.